Fate Therapeutics Inc., of San Diego, presented preclinical data showing that its WNT7, a protein analogue for the treatment of muscular dystrophy, produced dose-dependent muscle hypertrophy and several-fold expansion of the satellite stem cell population when given as an intramuscular injection in an MDX mouse model
Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research
The authors developed an animal model of AML and showed that leukemia stem cells in that model had higher levels of activity of a particular receptor tyrosine kinase, hematopoietic cell kinase or HCK...The authors hope that "RK-20449 offers a potential avenue for preventing and overcoming AML relapse" through targeting cancer stem cells
StemCells Inc., of Newark, Calif., added the Byers Eye Institute at Stanford University in Palo Alto, Calif., as a second site for the Phase I/II trial of its purified human neural stem cell candidate in dry age-related macular degeneration
Stem Cell Therapeutics Corp., of Toronto, said it executed a license agreement with University Health Network (UHN), developed in collaboration with MaRS Innovation, providing the company with exclusive worldwide rights to a clinical cancer stem cell program
Athersys Inc., of Cleveland, said the UK's Medicines and Healthcare Products Regulatory Agency approved its application to expand the ongoing Phase II study of MultiStem therapy, an off-the-shelf stem cell product, to patients who have suffered an ischemic stroke...Neuralstem Inc., of Rockville, Md., said it received approval from the FDA to start a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis
Gentium SpA, of Villa Guardia, Italy, said it requested a re-examination of the negative opinion adopted by the European Committee for Medicinal Products for Human Use (CHMP) March 22, regarding the marketing authorization application (MAA) submitted for defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy
In the prospective, randomized study, patients with chronic heart failure secondary to ischemic cardiomyopathy received treatment with their own stem cells engineered to become progenitors of cardiac cells
BioWorld International | Wednesday, April 17, 2013
stem cells Congestive heart failure Beginning a Phase I trial 3/22/13 Catabasis Pharmaceuticals Inc. (Cambridge, Mass.) CAT-2003 A conjugate of naicin and eicosapentaenoic acid Cardiovascular disease Started a Phase I trial 3/27/13 Gentium SpA (Villa Guardia, Italy) Defibrotide Comprises a complex mixture of the salts of single-stranded oligodeoxyribonucleotides obtained from the mucosa of pigs Veno-occlusive disease Administered defibrotide to the first subject in a Phase I study 3/27/13
stem cell transplantation therapy Received a negative opinion from the EMA's CHMP 3/25/13 Genzyme Corp. (Cambridge, Mass.) Kynamro Mipomersen Familial hypercholesterolemia EMA's CHMP confirmed a previous negative opinion against approval following a request for re-examination 3/25/13 Mast Therapeutics Inc. (San Diego) MST-188 Purified poloxamer 188 Sickle cell disease European Commission designated it an orphan medicinal product 3/26/13 ViroPharma Inc. (Exton, Pa.) Cinryze C1 inhibitor (human
the drug also met a key secondary endpoint 3/22/13 Biotie Therapies Corp. (Turku, Finland) SYN115 Tozadenant Parkinson's disease Phase IIb data showed significant reductions in mean placebo-corrected change from baseline in "off" time were observed with tozadenant 120 mg BID and 180 mg BID 3/22/13 BrainStorm Cell Therapeutics Inc. (New York) NurOwn Technology for the propagation and differentiation of autologous mesenchymal stem cells into nuerotrophic factor-secreting cells Amyotrophic lateral
12/404,841, for a method that uses expanded spinal cord stem cells, including NSI-566 stem cells, for the treatment of amyotrophic lateral sclerosis, or Lou Gehrig's disease
In the prospective, randomized study, patients with chronic heart failure secondary to ischemic cardiomyopathy received treatment with their own stem cells engineered to become progenitors of cardiac cells
StemCells Inc., of Newark, Calif., said it entered an agreement with the California Institute for Regenerative Medicine (CIRM), under which CIRM will provide about $19.3 million to help fund preclinical development and investigational new drug application (IND)-enabling activities of the firm's HuCNS-SC product candidate (purified human neural stem cells) for Alzheimer's disease
Stem Cell Therapeutics Corp., of Toronto, said it completed its merger with Trillium Therapeutics Inc., also of Toronto, after shareholders of Trillium voted overwhelmingly to support the merger...The deal adds Trillium's cancer stem cell therapy to SCT's portfolio
BNC101 is designed to target cancer stem cells, with preclinical data demonstrating functional activity against LGR5